Introduction
Aztreonam is a new monocyclic /Mactam antibiotic (Sykes et al., 1981) with high activity against aerobic Gram-negative bacteria. Previous studies have shown that aztreonam is eliminated predominantly through the kidneys and that its serum half-life is about 1 -6-1 -9 h (Swabb et al., 1982 a, b, c, Wise et al., 1982 . The present paper describes the in-vitro activity of aztreonam compared with that of cefotaxime against bacterial isolates from urological patients with complicated and/or hospital acquired urinary tract infections (UTI), the pharmacokinetics of aztreonam and the therapeutic efficacy of aztreonam compared with that of cefotaxime in the treatment of complicated and/or hospital acquired UTI.
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and Mueller-Hinton broth were obtained from Difco Laboratories, Detroit, Michigan, USA and Merck, Darmstadt, Germany. Nutrient broth and blood agar base no. 2 were from Oxoid Deutschland GmbH, WeseL, Germany.
Inulin was obtained from Laevosan, Linz, Austria; Conray 70* (a mixture of iothalamic acid, sodium salt and megluminate) and pure iothalamic acid were from Byk-Gulden, Konstanz, Germany.
In-vitro study: clinical isolates
In-vitro minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 strains isolated from the urine of urologjcal in-patients with complicated and/or hospital acquired UTT (bacterial counts ;> 10 3 cfu/ml). Only patients with monoinfections were included in the study.
Subjects
Group I. Nine elderly patients (8 male, 1 female) with a mean age of 72-6 years (range 64-82 years), a mean body weight of 65-3 kg (range 53-1-79-8 kg) and a mean height of l-63m (range 1-54-1-69 m) were recruited for the pharmacokinetic study. The subjects had serum creatinine levels < 15 g/1. Written informed consent was obtained.
Group II. The subjects of the clinical study were 39 urological patients (27 male, 12 female) between the ages of 18 and 83 years. They had complicated and or/hospital acquired UTI and significant bacteriuria with urinary counts of ^ 10 s cfu/ml. All patients gave informed written consent.
Pharmacokinetic study
Aztreonam, 1 g, was administered intravenously over 3min in 100 ml of sterile physiological saline containing 50g inulin and 20ml Conray 70*, corresponding to 13-2 g iothalamic acid. Blood samples were taken immediately before and 5, 10, 20, 30, 45, 60, 90 min and 2, 4, 6 and 8 h after the dose. Urine samples were collected before and at the following intervals: 0 to 2; 2 to 4; 4 to 6; 6 to 8 and 8 to 12 h after the administration of aztreonam. The urine volumes were measured and aliquots were taken for assay.
Clinical study
The subjects of the clinical study group were randomized and treated intravenously either with aztreonam (AZ) or with cefotaxime (CTX), 1 g bd, over 4-15 days. The patients had not received antimicrobial therapy within 4 weeks before the study. Bacterial urine cultures were performed prior to the therapy, during therapy, one or two days after treatment (post-treatment), and one to four weeks (one patient six weeks) later (follow-up). In addition urinalysis, haematology (erythrocyte, leucocyte and platelet counts) and chemistry profiles (creatinine, BUN, total bilirubin, alkaline phosphatase, SGOT, SGPT) were followed in each patient pre-and post-treatment. The patients were closely watched for local and systemic adverse reactions to the antibiotics. Bacteriological cure implied eradication of the primary offending organism and the absence of superinfection or reinfections with different species during the following therapy. The pathogens, isolated by standard microbiological techniques, were checked for purity on blood agar plates and their identities were confirmed by Gram's stain, colonial morphology and by use of the API-20 systems (API bioMerieux GmbH, Niirtingen, Germany).
Determination of the minimal inhibitory concentration (MIC)
For the in-vitro study the activities of aztreonam and cefotaxime were determined by the agar dilution technique using doubling dilutions of the antibiotics from 128 to 0-015 mg/1 in Mueller-Hinton agar (Merck) as the test medium. Inoculum size was 10*cfu using a multipoint inoculator (Dynatech). For the clinical study the activities of aztreonam and cefotaxime were assayed by the broth dilution method in MuellerHinton broth (Difco) as the test medium. The isolated clinical strains were grown overnight in nutrient broth (Oxoid) to give a viable count of about 10 9 cfu/ml. The final inoculum size was 5 x 10 s cfu/ml. After 18 h of incubation at 37°C the minimal inhibitory concentrations (MICs) were read by eye. The MIC was defined as the lowest concentration of the antibiotic that prevented visible growth of the micro-organism.
Assay of aztreonam
Aztreonam concentrations in serum and urine samples were determined microbiologically by the agar plate diffusion technique. The agar medium was antibiotic medium 1 and the test organism was Escherichia coli 6311/65 (Hoescht AG). Serum urine standards ranging from 0-5 to 100mg/1 were prepared in human serum and in phosphate buffered saline, respectively. Samples and standards were assayed in triplicate. After incubation overnight at 37°C the inhibition zones were measured with an accuracy of 01 mm.
Assay ofinulin
Inulin in serum and urine was estimated chemically according to Heyrovsky's method (Heyrovsky, 1956 ). The chemical estimation of inulin is based on the hydrolysis of inulin to fructose, which is determined photometrically by the colour formed upon reaction with indole-3-acetic acid in hydrochloric acid. The interference by glucose was found to be negligible.
Assay of iothalamic acid
Iothalamic acid was determined by HPLC according to a published procedure (Kees, Grobecker & Naber, 1984) with minor modifications. In brief, serum (400 nl) was deproteinized with acetonitrile (400 ul). The latter was removed by extraction into dichloro-methane (2 ml) and an aliquot of the aqueous phase containing the iothalamic acid was injected into the chromatographic system. Urine was centrifuged and injected directly after dilution (1:20) with water. The liquid chromatograph consisted of a pump M 6000 A, an autoinjector WISP 710 B, a fixed wavelength detector M 440, operating at 254 nm, a data module M 730 and a system controller M 720, all from Waters, Ass., D-6236 Eschborn, Germany. For separation a HIBAR* column (ID 125x4 mm) was used prefilled with LiChrosorb* RP 18 silica (particle size 5 urn) from Merck, D-6200 Darmstadt, Germany. The mobile phase was a mixture of 880 ml water, 120 ml acetonitrile, 1 -40 g sodium acetate trihydrate, and 450 mg tetrabutylammonium hydrogensulphate. The pH was adjusted to 4-8 with acetic acid. The flow rate was maintained at lOml/min resulting in a back pressure of 110 bar and a retention time of 4-0 min for iothalamic acid.
Pharmacokinetic analysis
The pharmacokinetic parameters were obtained from serum concentrations by use of an open two compartment model and the following equation for fitting the experimental data: concentration=y4.e-(rl +B.e~* 1 . 
•Number of isolates. 
Results

In-vitro study
The MIC values of aztreonam and cefotaxime for the 400 isolates cultured from the urine are shown in Table I . The MICs of aztreonam against all but nine of the 265 Gram-negative isolates were 8 mg/1 or lower. The MICs against all but two of the 134 Gram-positive isolates were 128 mg/1 or higher. Cefotaxime inhibited 90-2% of the Gram-negative and 470% of the Gram-positive isolates at 8 mg/1 or lower.
Pharmacokinetic study
The serum concentrations after injection of 1 g of aztreonam are shown in Figure 1 . The mean ±S.D. (range) serum half-life amounted to 2-7±0-8h (1-8-4-3 h). The mean ±s.D. (range) urinary concentrations of aztreonam were: 0-2 h 1598 ±554 mg/1 (906-2716mg/l), 2-4h 1195±598 (647±2293), 4-6h 964±564 (272-1799), 6-8h 443±198 (109)-795), and 8-12 h 244± 140 mg/1 (7-9-449 mg/1).
In Table II the calculated pharmacokinetic parameters of aztreonam, inulin and iothalamic acid are listed. The mean serum half-life of aztreonam (2-7 h) and iothalamic acid (2-7 h), as well as the volume of distribution (each 27-5% of body weight) were slightly higher than the corresponding parameters of inulin which is a marker for the extracellular space. On the other hand, total clearances were of the same order (around 90 ml/min). The mean urinary recovery (Figure 2 ) within 12 h was 70% for aztreonam and nearly 90% for the other two compounds. The high standard deviation of the urinary recovery of aztreonam is striking.
The mean ± SJX (range) urinary recovery of aztreonam with respect to inulin was 82 ± 36% (33-143%) whereas that of iothalamic acid was 103 ± 5% (96-111 %).
There was no statistically significant linear correlation between the serum clearances of aztreonam and inulin, but there was between iothalamic acid and those of inulin (r = 0-91;J»< 0-05). •One patient did not receive iothalamic acid; another patient was injected with a substance which interfered with the assay of iothalamic acid. 
Clinical study
In the patients with UTIs the following causative organisms (AZ/CTX) were found: E. coli (8/9), Proteus mirabilis (3/5), Pseudomonas aeruginosa (1/3), Klebsiella pneumoniae (5/0), Pr. vulgaris (1/1), Providencia stuartii (0/1), Enterobacter sp. (1/1), Citrobacter freundii (0/2). There were three mixed infections (1/2) with E. coli and enterococci or two different Proteus spp. respectively.
The causative organisms were eradicated in all patients in the aztreonam group and in 19 of 20 patients in the cefotaxime group (Table III) .
One to two days after treatment significant bacteriuria was still found in three out of 19 patients in the aztreonam and in two out of 20 in the cefotaxime group. Definite cure (no significant bacteriuria in post treatment or follow up among specimens) was obtained in five out of 18 patients in the aztreonam and in seven out of 20 patients in the cefotaxime group. There were three superinfections (different species present one to two days after therapy), seven relapses (same species present again at follow up), three reinfections (different species found at follow up) in the aztreonam group (one patient was not assessable); and one failure (same species one to two days after therapy), one superinfection, six relapses and five reinfections in the cefotaxime group. There was no significant difference in therapeutic efficacy between the two antibiotics.
In a total of nine patients (aztreonam 5, cefotaxime 4) all with pyuria, enterococci were cultured from the urine on at least two occasions after the antibacterial treatment. Seven of these patients were treated because of urinary tract infections which occurred postoperatively. One patient had stones in the bladder and one patient a renal tumour. This last patient was treated with aztreonam for four days because of an E. coli infection. Since the patient remained febrile and superinfection with enterococci occurred, treatment was successfully changed to bacampiciUin. Both antibiotics were well tolerated so that it was not necessary to stop therapy because of adverse reactions. There were no biochemical signs or symptoms of renal, hepatic or haematological toxicity.
Discussion
The therapeutic spectrum of cefotaxime includes the majority of staphylococci but not enterococci. All Gram-positive strains are resistant to aztreonam. The Gram-negative strains cultured from the urine of 400 urological in-patients were comparably sensitive to aztreonam and cefotaxime. Aztreonam, however, showed a greater activity against Pseudomonas species.
The pharmacokinetics of aztreonam exhibited a prolonged plasma half life (2-7 h) in elderly patients as compared to healthy volunteers (1-6-1-9 h). In an earlier study of cefotaxime pharmacokinetics in geriatric patients (Naber & Adam, 1980) , a prolonged half life of about two hours was also found. In both the studies plasma concentrations showed a fairly wide range. In elderly patients with prolonged half lives of aztreonam and cefoxatime, doses given twice daily should be sufficient for the treatment of UTI. The total plasma clearances of aztreonam, inulin and iothalamic acid are very comparable, indicating that the major route by far for the renal excretion of aztreonam is via glomerular filtration. Since at low concentrations the chemical analysis of inulin is difficult, plasma concentrations could only be measured up to 4-6 h after iv administration of 5 g. Therefore in the study iothalamic acid was also administered. This compound, clinically used as contrast medium for urography, is as suited as inulin for the determination of glomerular filtration rate (Sigman, Elwood & Knox, 1965) . After injection of 20 ml Conray 70*, corresponding to 13-2 g iothalamic acid, plasma concentrations can easily be measured by HPLC up to 24 h after injection. During and immediately after therapy high success rates were achieved with both the antibiotics. However, definite cure (no bacteriuria found within follow up period), could only be observed in about one-third of the patients regardless of the antibiotic used. Comparable results were obtained in two other studies of urological patients treated with different antimicrobial compounds (Naber & Bauernfeind, 1982; Naber & Wittenberger, 1985) . Relapses and reinfections are common phenomena following the treatment of complicated UTI. In these cases underlying anatomical or functional abnormalities may serve as a nidus of infection and prevent complete eradication of bacteria.
